Evidence map›Paper›PMID 39527398›Full record

ArticlePharmacoEconomics2025

Value-Based Healthcare in Practice: IDEATE, a Collaboration to Design and Test an Outcomes-Based Agreement for a Medicine in Wales.

Jessica R Burton, Kate Halsby, Graciela Sáinz de la Fuente, Jonathan Pearson-Stuttard, Rebecca Sloan, Thomas Porter, Gareth John, Andrew Warburton, Jennifer Selby, Gail Povey and 5 more

Abstract read
In one paragraph

Article in PharmacoEconomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jessica R BurtonUK Health and Value, Outcomes Innovation and Evidence, Pfizer Ltd, Walton Oaks, Tadworth, UK.ORCID http://orcid.org/0009-0004-9115-8782
Kate HalsbyUK Health and Value, Outcomes Innovation and Evidence, Pfizer Ltd, Walton Oaks, Tadworth, UK. Kate.halsby@pfizer.com.
Graciela Sáinz de la FuenteUK Health and Value, Outcomes Innovation and Evidence, Pfizer Ltd, Walton Oaks, Tadworth, UK.
Jonathan Pearson-StuttardHealth Analytics, Lane Clark and Peacock LLP, London, UK.
Rebecca SloanHealth Analytics, Lane Clark and Peacock LLP, London, UK.
Thomas PorterHealth Analytics, Lane Clark and Peacock LLP, London, UK.
Gareth JohnDigital Health and Care Wales, Cardiff, Wales, UK.
Andrew WarburtonDigital Health and Care Wales, Cardiff, Wales, UK.
Jennifer SelbyDigital Health and Care Wales, Cardiff, Wales, UK.
Gail PoveySouth West Wales Cancer Centre, Swansea Bay University Health Board, Swansea, Wales, UK.
Ruhe ChowdhuryUK Oncology, Medical Affairs, Pfizer Ltd, Walton Oaks, Tadworth, UK.
Catherine BaleBetsi Cadwaladr University Health Board, Mold, Wales, UK.
Mark DaviesSwansea University Health Board, Swansea, Wales, UK.
Emma Clifton-BrownUK Health and Value, Outcomes Innovation and Evidence, Pfizer Ltd, Walton Oaks, Tadworth, UK.
Hamish LaingValue-Based Health and Care Academy, Swansea University, Swansea, Wales, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop a sustainable, scalable methodology for the design of outcome-based agreements (OBAs) that works on the ground and dynamically overcomes historical challenges.

methodsProject IDEATE co-created solutions to known (and emergent) challenges via iterative workshops and real-world data analysis to develop and refine a hypothetical model for an OBA in a trusted research environment. A cross-disciplinary collaboration between National Health Service (NHS) Wales, industry and academia was developed. Data were collected from Welsh national datasets and used to construct a novel linked dataset. OBA scenarios, with different contract parameters, were analysed to assess impact on the proportion of contract payment due and the volatility of payments.

resultsAn approved, in market, locally advanced and metastatic breast cancer treatment was selected as the test case. The total number of patients in the treatment cohort (2017-2020) was n = 99, and 286 in the control cohort (2014-2016). The final outcome variables selected were: (1) 1-year survival,( 2) intolerance to treatment (deferral), and (3) the total days disrupted by care. The primary scenario included all three outcomes measured at the population level and used a linear payment model. Volatility analyses demonstrated contract parameters can dramatically alter the contract output with greatest risk from a single, binary outcome contract design.

conclusionsThe design of an OBA is a complex process that requires a multi-disciplinary approach. By assessing solutions to data, outcomes and contracting challenges, IDEATE provides a strong foundation for future success of OBAs in the UK. Outcome-based agreements (OBAs) are a way to pay for medicines if they help patient health in a specific way over time. These agreements can make it faster for people to get new medicines, but they also have challenges, like needing a lot of time and effort to manage them. A team from the NHS Wales, life sciences, and Swansea University created Project IDEATE to find a better way to design OBAs and solve some of these problems. Welsh datasets were used to create a new breast cancer dataset to test different OBAs and see how payments would change. A breast cancer treatment was used for the project. The project had 99 patients who got the medicine (2017-2020) and 286 patients who had breast cancer but did not get the medicine (2014-2016). Three health outcomes were measured: (1) living for one year after treatment, (2) patients needing to stop the medicine, and (3) days spent in care. The main OBA option we tested used all three health outcomes; the more the outcomes improved, the more the payments could go up until they hit the highest amount agreed. The analysis showed that the way an OBA is designed can make a big difference in how stable or risky it is, especially if one of the health outcomes has only two options. Project IDEATE showed that making an OBA can be hard, but when people from different fields work together, they can overcome many challenges and succeed.

Indexed as

Breast NeoplasmsDelivery of Health CareOutcome Assessment, Health CareFemaleHumansModels, EconomicState MedicineValue-Based Health CareWales

Identifiers

PMID39527398
PMCPMC11782430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.